The impact of adjuvant EGFR-TKIs and 14-gene molecular assay on stage I non–small cell lung cancer with sensitive EGFR mutations

BACKGROUND: Currently, the role of EGFR-TKIs as adjuvant therapy for stage I, especially IA NSCLC, after surgical resection remains unclear. We aimed to compare the effect of adjuvant EGFR-TKIs with observation in such patients by incorporating an established 14-gene molecular assay for risk stratif...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Yu, Lin, Yuechun, Fu, Wenhai, He, Qihua, Liang, Hengrui, Zhong, Ran, Cheng, Ran, Li, Bingliang, Wen, Yaokai, Wang, Huiting, Li, Jianfu, Li, Caichen, Xiong, Shan, Chen, Songan, Xiang, Jianxing, Mann, Michael J., He, Jianxing, Liang, Wenhua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511786/
https://www.ncbi.nlm.nih.gov/pubmed/37745018
http://dx.doi.org/10.1016/j.eclinm.2023.102205

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10511786/
https://www.ncbi.nlm.nih.gov/pubmed/37745018
http://dx.doi.org/10.1016/j.eclinm.2023.102205

Ejemplares similares